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ORIGINAL RESEARCH
Impact of ST-Segment–Elevation Myocardial 
Infarction Regionalization Programs on 
the Treatment and Outcomes of Patients 
Diagnosed With Non–ST-Segment–Elevation 
Myocardial Infarction
Juan Carlos C. Montoy , MD, PhD; Yu-Chu Shen , PhD; Ralph G. Brindis , MD, MPH;  
Harlan M. Krumholz , MD, SM; Renee Y. Hsia , MD, MSc
BACKGROUND: Many communities have implemented systems of regionalized care to improve access to timely care for patients 
with ST-segment–elevation myocardial infarction. However, patients who are ultimately diagnosed with non–ST-segment–
elevation myocardial infarctions (NSTEMIs) may also be affected, and the impact of regionalization programs on NSTEMI 
treatment and outcomes is unknown. We set out to determine the effects of ST-segment–elevation myocardial infarction 
regionalization schemes on treatment and outcomes of patients diagnosed with NSTEMIs.
METHODS AND RESULTS: The cohort included all patients receiving care in emergency departments diagnosed with an NSTEMI 
at all nonfederal hospitals in California from January 1, 2005 to September 30, 2015. Data were analyzed using a difference-
in-differences approach. The main outcomes were 1-year mortality and angiography within 3 days of the index admission. 
A total of 293 589 patients with NSTEMIs received care in regionalized and nonregionalized communities. Over the study 
period, rates of early angiography increased by 0.5 and mortality decreased by 0.9 percentage points per year among the 
overall population (95% CI, 0.4–0.6 and −1.0 to −0.8, respectively). Regionalization was not associated with early angiography 
(−0.5%; 95% CI, −1.1 to 0.1) or death (0.2%; 95% CI, −0.3 to 0.8).
CONCLUSIONS: ST-segment–elevation myocardial infarction regionalization programs were not statistically associated with 
changes in guideline-recommended early angiography or changes in risk of death for patients with NSTEMI. Increases in the 
proportion of patients with NSTEMI who underwent guideline-directed angiography and decreases in risk of mortality were 
accounted for by secular trends unrelated to regionalization policies.
Key Words: angiography ■ mortality ■ non–ST-segment–elevation myocardial infarction ■ ST-segment–elevation myocardial infarction
Many communities have established region-alized systems of care for ST-segment–ele-vation myocardial infarction (STEMI) over the 
past decade.1–3 Although this focus on the organi-
zation and delivery of care may improve treatment 
and outcomes for patients with STEMI, regionaliza-
tion could have unintended effects on patients with 
non–ST-segment–elevation myocardial infarction 
(NSTEMI), a condition with high prevalence and sig-
nificant mortality, and for which angiography and 
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percutaneous coronary intervention (PCI) are associ-
ated with better outcomes.4–13
Specifically, STEMI regionalization could affect vol-
ume and staffing in both PCI and non-PCI centers, po-
tentially influencing the type of care given to patients with 
NSTEMI.14,15 It also could improve outcomes through 
several mechanisms, including through increased ad-
herence to guidelines recommending angiography, via a 
volume-outcomes relationship, or through external fac-
tors, such as better follow-up care.16 However, whether 
regionalization of STEMI care impacts treatments and 
outcomes for patients experiencing NSTEMIs, whether 
beneficial, neutral, or harmful, remains unexplored.
In this study, we set out to determine whether and to 
what extent STEMI regionalization might impact treat-
ment and outcomes for patients with NSTEMIs. We hy-
pothesized that risk-adjusted outcomes for patients with 
NSTEMIs improved more in regionalized compared with 
nonregionalized communities. We also hypothesized that 
the probability of receiving invasive therapy (ie, guideline-di-
rected angiography and possible PCI within 72  hours) 
increased for patients with NSTEMI in regionalized com-
munities compared with nonregionalized communities.
METHODS
Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject confi-
dentiality protocols may be sent to the California Office 
of Statewide Health Planning and Development at 
oshpd.ca.gov.
Conceptual Model
STEMI regionalization could change the type of care 
given to patients with NSTEMI in several ways. First, 
after regionalization, a greater proportion of patients 
with NSTEMIs could receive care at PCI-capable 
hospitals if emergency medical services providers 
transport them to PCI centers because of immediate 
concern for a possible STEMI or if they self-present to 
PCI-capable centers. Second, patients with NSTEMI 
may be more likely to undergo timely invasive therapy 
(ie, a PCI within 72  hours during index hospitaliza-
tion).17 This is particularly important given mounting 
evidence and an American College of Cardiology/
American Heart Association guideline recommending 
that most patients with NSTEMI should receive timely 
invasive therapy (ie, PCI within 72 hours) as a first-line 
treatment.5,11–13 Third, PCI centers may provide better 
NSTEMI care because of experience derived from a 
higher volume of treated patients.15 Finally, regionalized 
centers may provide better follow-up care, including 
medical optimization for secondary prevention.16
However, there is a possibility that treatment and 
outcomes could worsen under certain conditions: first, 
if the focus on STEMIs leads physicians at either PCI 
or non-PCI centers to focus less on caring for patients 
with NSTEMIs; second, if non-PCI centers fall out of 
practice because they admit and treat fewer NSTEMIs; 
and, finally, if regionalization results in fragmentation of 
local care and thus poorer follow-up and secondary 
prevention.
A difference-in-differences approach compares the 
changes in treatment and outcomes for counties that 
regionalized (difference between preregionalization 
and postregionalization) compared with the difference 
over the same time period for counties that were not 
regionalized. This approach helps identify the asso-
ciation between the change in policy and changes in 
treatment and outcomes separate from the trends in 
treatment and outcomes occurring for reasons other 
than the change in policy, such as changes in the epi-
demiological features of NSTEMI.
Study Sample and Data Sources
We linked nonpublic discharge data and non-
public emergency department data from the 
California Office of Statewide Health Planning and 
Development for the study period from January 1, 
2005 to September 30, 2015. As Office of Statewide 
Health Planning and Development records data from 
all emergency department and inpatient encounters 
CLINICAL PERSPECTIVE
What Is New?
• In this study of almost 300  000 patients with 
non–ST-segment–elevation myocardial infarc-
tion, likelihood of early angiography increased 
by 0.5 and mortality decreased by 0.9 percent-
age points per year over the course of >10 years.
• Regionalization of care for ST-segment–eleva-
tion myocardial infarction was not associated 
with changes in angiography, percutaneous 
coronary intervention, or 1-year mortality of pa-
tients presenting with non–ST-segment–eleva-
tion myocardial infarction.
What Are the Clinical Implications?
• Treatment and outcomes for non–ST-segment–
elevation myocardial infarction have improved 
recently, but ST-segment–elevation myocardial 
infarction regionalization programs were not 
responsible for these changes and policy mak-
ers should not expect ST-segment–elevation 
myocardial infarction regionalization programs 
to have large unintended consequences for pa-
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at all nonfederal, general acute-care hospitals, and 
patients are identified by record linkage number, we 
comprehensively observed procedures and diag-
noses for all patients with NSTEMI during the study 
period. All patient encounters in the data, identified 
as having an International Classification of Diseases, 
Ninth Revision (ICD-9), code for NSTEMI (410.70 and 
410.71) or STEMI (410.xx, except 410.7x and 410.x2) 
during the study period, were included in our analy-
sis. We linked each patient observation to California 
Vital Statistics data through 2013 (the most recent 
data available) using a unique patient identifier.
Hospitals and counties were linked to the STEMI 
Network Database and Hospital STEMI Designation 
data set, 2 data sets we previously collected for re-
lated research.18,19 These data sets contain the de-
gree of regionalization and dates of implementation 
of California’s 33 local emergency medical services 
agencies, which provide emergency medical ser-
vices for California’s 58 counties. Although the term 
regionalization is used broadly in the literature as 
“matching of medical resources to patient needs to 
maximize health benefits and outcomes while min-
imizing cost and use of resources over a specified 
geographic area,”20 this leaves some degree of sub-
jectivity in defining regionalization. Following previous 
work conducted by the research team,18,19 we de-
noted a county as achieving complete regionalization 
on and after the year that 95% of its local emergency 
medical services system has: (1) emergency medical 
systems that direct prehospital transport to bypass 
the nearest hospitals that do not offer emergent PCI 
to facilities that offer emergent PCI for patients with 
STEMI; and (2) interhospital transfer protocols specif-
ically for patients with STEMI.20
Outcomes
The primary outcomes were angiography within 
3 days and death at 1 year. We chose angiography 
instead of PCI because this represents an attempt at 
an invasive strategy regardless of whether a culprit 
lesion was identified or subject to intervention. We 
identified angiography using ICD-9 procedure codes 
3721-3 and 8850-7. Secondary outcomes included 
death at 7, 30, and 90  days, as identified through 
the linked vital statistics files. As a sensitivity analy-
sis, we also used receipt of PCI as another outcome 
(Table S1).
Statistical Analysis
We used a multivariable linear regression model to 
measure the association between regionalization 
status of each patient’s county of residence and 
risk of death within 1 year of NSTEMI diagnosis. The 
model included regionalization status, year, patient 
characteristics, hospital characteristics, and treat-
ments. An indicator for regionalization was specified 
as one on and after the year in which a community 
achieved STEMI regionalization, and zero otherwise. 
Our model included year of encounter to account 
for secular trends common across all counties, re-
gardless of regionalization status. Patient charac-
teristics included sex, age group, race/ethnicity, 
comorbidities (categorized according to Elixhauser 
comorbidity index), and expected insurance. Race/
ethnicity categories included Asian, Black, Hispanic, 
and Native American. Age groups were defined as 
<40, 40 to 64, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 
and ≥85 years. Hospital characteristics included an-
nual emergency department volume, critical access 
designation, teaching hospital designation, govern-
ment hospital, not-for-profit status, and whether the 
hospital was PCI capable (defined as capable for a 
given year if that year’s PCI procedures were ≥5) or 
non-PCI capable. We included an interaction term 
between PCI capability and regionalization status to 
measure differences between non-PCI centers and 
PCI centers separately within nonregionalized and 
regionalized communities. Angiography (without PCI) 
within 3  days and PCI within 3  days were both in-
cluded as indicators. We analyzed secondary out-
comes for death (7, 30, and 90 days) using the same 
model specification. We used a multivariable linear 
regression model to measure the association be-
tween regionalization status of each patient’s county 
of residence and the likelihood of undergoing angi-
ography within 3 days of diagnosis. This model used 
angiography as the outcome of interest and excluded 
PCI; it was otherwise identical to the mortality model. 
The PCI model used as a sensitivity analysis used 
the same specification as the angiography model, 
with PCI as the outcome of interest. All models used 
county fixed effects to account for unobserved dif-
ferences across counties that did not vary over the 
study period. Given our sample size of ≈290 000, we 
had 80% power at an α of 0.05 to detect a 1 percent-
age point difference in likelihood of angiography or 
death. SEs were clustered at the county level for all 
models. All analyses were conducted using STATA 
15 (StataCorp, College Station, TX). Permission to 
conduct this study was granted by the University of 
California, San Francisco, Institutional Review Board 
with a waiver of informed consent.
RESULTS
During our 10-year study period, we evaluated 
293  589 patients with NSTEMI; of these patients, 
78  923 (26.8%) received care in communities that 
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and 214  666 (73.2%) received care in hospitals in 
STEMI-regionalized communities (Table  1). Patients 
in regionalized communities were more likely to be 
minorities and had more comorbidities than patients 
in nonregionalized communities; they did not differ 
by age or sex.
Over the study period, the incidence of NSTEMI 
increased. As more counties became regionalized, 
an increasing proportion of patients received care in 
regionalized communities and a decreasing propor-
tion received care at nonregionalized communities 
(Figure 1). By 2014, all communities had regionalized. 
Over the study period, most patients with NSTEMI re-
ceived care in PCI-capable hospitals; they had a higher 
likelihood of doing so in regionalized than in nonregion-
alized communities (69.9% regionalized and 63.3% 
nonregionalized; χ2 P<0.0005).
When controlling for patient and hospital char-
acteristics, the multivariable regression examining 
regionalization and probability of undergoing an-
giography (Table  2) did not show any impact from 
regionalization (−0.3 percentage points; 95% CI, 
−1.2 to 0.5 percentage points). The probability of un-
dergoing angiography increased by 0.5 percentage 
points each year (95% CI, 0.4–0.6 percentage points) 
across all counties, regardless of regionalization sta-
tus. The strongest predictor of whether a patient 
underwent angiography was whether the hospital 
was PCI capable (49.4 percentage points; 95% CI, 
48.8–50.2 percentage points). There was no differ-
ence in this association between regionalized and 
nonregionalized communities (interaction, −0.2 per-
centage points; 95% CI, −1 to 0.6 percentage points). 
Patients were less likely to undergo angiography at 
critical access hospitals (−10.0 percentage points; 
95% CI, −15.7 to −4.3 percentage points) or teaching 
hospitals (−3.5 percentage points; 95% CI, −4.1 to 
−2.8 percentage points). In terms of patient demo-
graphics, increasing age (>70 years) and most (23 of 
29) comorbidities were associated with a lower like-
lihood of angiography (coefficients for comorbidities 
not presented). Patients with Medicare and Medicaid 
insurance were less likely to undergo angiography 
than those with private insurance (−2.8 percentage 
points [95% CI, −3.3 to −2.2 percentage points] and 
−3.5 percentage points [95% CI, −4.2 to −2.8 per-
centage points], respectively). Black patients had 
a 5.6 percentage point lower probability of receiv-
ing angiography (95% CI, −6.3 to −4.9 percentage 
points) compared with non-Hispanic White patients.
Figure 2 shows trends for the proportion of patients 
with NSTEMI undergoing angiography within 30 days 
of diagnosis. There was a steady increase in the pro-
portion of patients who received angiography over 
the study period; most of this was attributable to the 
increased proportion of patients undergoing angiogra-
phy within 2 days of diagnosis.
The probability of death within 1  year of NSTEMI 
diagnosis decreased over time across all counties in 
the multivariable model (−0.9 percentage points per 
year; 95% CI, −1.0 to −0.8 percentage points per year; 
Table 3). No significant association between regional-
ization and death was found (0.0 percentage points; 
95% CI, −0.8 to 0.7 percentage points). Receiving care 
in a PCI center was associated with a 3.7 percentage 
point increased risk of death (95% CI, 3.0–4.3 percent-
age points). This relationship did not differ between 
regionalized and nonregionalized communities: inter-
action between PCI capability and regionalization was 
0.4 percentage points (95% CI, −0.3 to 1.2 percent-
age points). The probability of death increased with in-
creasing age and with most (21 of 29) comorbidities. 
Undergoing angiography within 3 days of NSTEMI di-
agnosis was associated with a 10.1 percentage point 
decrease in risk of death (95% CI, −10.5 to 9.7 percent-
age points), and PCI within 3 days was associated with 
a 10.5 percentage point decrease in mortality (95% 
CI, −11.0 to −10.1 percentage points). Regionalization 
was not associated with risk of death across different 
time horizons: 7 days, 30 days, 90 days, and 1 year 
(Figure S1).
DISCUSSION
In this retrospective cohort study from 2005 through 
2015 of nearly 294  000 patients with NSTEMIs, we 
found that regionalization was not associated with 
significant changes in the likelihood of patients who 
received timely angiography or decreased mortality. 
Over the 10-year study period, the proportion of pa-
tients with NSTEMI undergoing angiography increased 
and their risk of death decreased, but these changes 
were not attributable to regionalization.
Our study is, to our knowledge, the first analysis 
of the relationship between regionalization of STEMI 
care and the treatment and outcomes for patients with 
NSTEMI. Previous work on STEMI regionalization has 
focused on the process of establishing such programs 
and intermediate outcomes, such as door-to-balloon 
times.19,21,22 These studies address primary questions 
about STEMI regionalization programs, but do not 
consider possible impacts on the management of pa-
tients with NSTEMI. The recent literature on NSTEMIs 
does include evaluations of incidence (eg, the impact 
of newer troponin assays and changes in patient de-
mographics),23 treatment (timing of and selection of 
patients for PCI),11,24,25 and outcomes (mortality).26 
However, such analyses have not considered these 
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Table 1. Patient and Hospital Characteristics
Characteristics Not Regionalized (n=78 923) Regionalized (n=214 666) P Value
Patient characteristics
Women 33 126 (42) 89 864 (41.9) 0.545
Age, median (IQR), y 70.0 (58–80) 69.0 (58–80) 0.7942
Race/ethnicity
White 53 194 (67) 122 510 (57) <0.0005
Black 5205 (7) 18 143 (8)
Hispanic 10 712 (14) 43 799 (20)
Asian 6589 (8) 20 883 (10)
Insurance
Private 19 257 (24) 46 797 (22) <0.0005
Medicare 49 875 (63) 134 368 (63)
Medicaid 5176 (7) 20 901 (10)
Indigent 1225 (2) 3617 (2)
Self-pay 2194 (3) 5726 (3)
Other 1184 (2) 3253 (2)
Comorbidities
Anemia 17 311 (22) 52 943 (25) <0.0005
Arrhythmia 129 (0) 416 (0) 0.094
Arthritis 1804 (2) 5480 (3) <0.0005
Cancer 741 (1) 2313 (1) 0.001
Congestive heart failure 27 663 (35) 77 918 (36) <0.0005
Coagulopathy 3088 (4) 11 495 (5) <0.0005
COPD 17 913 (23) 46 073 (21) <0.0005
Depression 5403 (7) 13 732 (6) <0.0005
Dementia 2420 (3) 6076 (3) <0.0005
Diabetes mellitus, uncomplicated 22 036 (28) 60 246 (28) 0.408
Diabetes mellitus with chronic complications 8883 (11) 31 158 (15) <0.0005
Fluid and electrolyte disorders 15 492 (20) 48 712 (23) <0.0005
HIV 159 (0) 420 (0) 0.796
Hypertension 59 367 (75) 170 802 (80) <0.0005
Hypothyroid 9226 (12) 26 955 (13) <0.0005
Liver disease 1374 (2) 4782 (2) <0.0005
Lymphoma 423 (1) 1377 (1) 0.001
Metastatic cancer 1945 (12) 5459 (3) 0.249
Neurological disorder 4998 (6) 14 915 (7) <0.0005
Obesity 10 211 (13) 33 701 (16) <0.0005
Paralysis 2221 (3) 6016 (3) 0.805
Psychoses 1925 (2) 8287 (4) <0.0005
Pulmonary circulation disorder 3445 (4) 11 428 (5) <0.0005
Renal failure 16 995 (22) 62 573 (29) <0.0005
Substance abuse 3853 (5) 12 352 (6) <0.0005
Ulcer, peptic 71 (0) 91 (0) <0.0005
Vascular disease 10 456 (13) 34 381 (16) 0.153
Valvular disease 11 201 (14) 30 097 (14) <0.0005
Weight loss 1534 (2) 8702 (4) <0.0005
Hospital characteristics
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The absence of a positive finding contributes to 
an increased understanding of the implications of 
STEMI regionalization programs. In previous work, we 
found that regionalization was not associated with a 
significant impact on whether patients with NSTEMI 
received care in PCI-capable hospitals: likelihood of 
patients with NSTEMI receiving care in PCI-capable 
hospitals increased by only 2.2 percentage points. 
We thus did not expect to find a difference in treat-
ment or outcomes caused by increased likelihood of 
care in PCI-capable hospitals and herein focused on 
whether the care patients received (ie, angiography 
and possible PCI) changed over the regionalization 
process.
Our analysis tested for differences in treatment and 
outcomes between regionalized and nonregionalized 
communities, and tested for differences between PCI 
and non-PCI centers within regionalized communities. 
This approach is important because there could be 
changes at the population level, and changes within 
the population that are obscured by a population-level 
analysis. For example, regionalization could lead to im-
provements in treatment and outcomes at PCI cen-
ters and worsening at non-PCI centers, but if these 
Characteristics Not Regionalized (n=78 923) Regionalized (n=214 666) P Value
Critical access hospital 135 (0.2) 185 (0.1) <0.0005
Teaching hospital 7034 (9) 20 829 (10) <0.0005
Government hospital 10 511 (13) 29 243 (14) 0.028
Not for profit 57 746 (73) 147 468 (69) <0.0005
Catheterization laboratory in hospital 49 945 (63) 150 034 (70) <0.0005
Values are number (percentage) unless otherwise stated. Race/ethnicity: Native American, other, and invalid combine to <5% of the sample. P values for 
age and ED volume calculated using t test; all other P values from the Pearson χ2 test for independence between samples. COPD indicates chronic obstructive 
pulmonary disease; ED, emergency department; and IQR, interquartile range.
Table 1. Continued
Figure 1. Non–ST-segment–elevation myocardial infarction (NSTEMI) incidence, according to regionalization status.
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are similar in magnitude, a population-level analysis 
will find no net effect. We did not find this was the 
case; there was no evidence that regionalization led 
to changes compared with nonregionalized commu-
nities, nor was there evidence that treatment and out-
comes changed within regionalized communities. The 
most likely interpretation of our finding is that STEMI 
regionalization may not have impacted the manage-
ment strategy of NSTEMIs, with no discernable effect 
on 1-year mortality.
Because of the mounting evidence of the use of 
early PCI for patients with NSTEMI that became appar-
ent around the same time that STEMI regionalization 
programs took shape, it is possible that hospitals ad-
opted timely PCI for NSTEMI before regionalization and 
thus there was no apparent effect of regionalization. 
Alternatively, hospitals could have increased their angi-
ography capability in preparation for regionalization and 
thus had no apparent change in treatment because of 
regionalization. However, the lack of association be-
tween regionalization and treatment and outcomes 
suggests that neither of these changes took place, with 
instead slow adoption of a timely invasive strategy in the 
management of NSTEMI over the study period sepa-
rate from regionalization. The proportion of patients we 
observed undergoing timely angiography was similar 
to the proportion found in other observational studies 
over similar time periods,17,27,28 although lower than 
that reported by the NCDR (National Cardiovascular 
Data Registry) ACTION (Acute Coronary Treatment 
Table 2. Probability of Undergoing Catheterization Within 3 Days of Admission
Variable Coefficient 95% CI P>t
Regionalized −0.003 −0.012 to 0.005 0.415
Year 0.005 0.004 to 0.006 <0.0005
Patient characteristics
Women −0.031 −0.034 to −0.027 <0.0005
Age group, y
40–64 0.014 0.000 to 0.027 0.048
65–69 −0.003 −0.018 to 0.012 0.689
70–74 −0.024 −0.039 to −0.009 0.001
75–79 −0.060 −0.075 to −0.046 <0.0005
80–84 −0.128 −0.142 to −0.113 <0.0005
85–99 −0.289 −0.303 to −0.274 <0.0005
Race/ethnicity
Black −0.056 −0.063 to −0.049 <0.0005
Hispanic 0.001 −0.003 to 0.006 0.56
Asian 0.002 −0.004 to 0.008 0.594
Insurance
Medicare −0.028 −0.033 to −0.022 <0.0005
Medicaid −0.035 −0.042 to −0.028 <0.0005
Indigent 0.039 0.026 to 0.052 <0.0005
Self-pay −0.009 −0.019 to 0.002 0.102
Other −0.007 −0.021 to 0.007 0.316
Hospital characteristics
Catheterization laboratory within hospital 0.495 0.488 to 0.502 <0.0005
Catheterization laboratory×regionalized −0.002 −0.010 to 0.006 0.58
ED volume (log) 0.006 0.003 to 0.009 <0.0005
Critical access hospital −0.100 −0.157 to −0.043 0.001
Teaching hospital −0.035 −0.041 to −0.028 <0.0005
Government hospital 0.009 0.002 to 0.016 0.008
Not for profit 0.002 −0.003 to 0.007 0.376
County population (log) 0.439 0.340 to 0.538 <0.0005
Multivariable regression also includes other race/ethnicity categories (Native American, other, and invalid) and comorbidities (indicator variable for each 
Elixhauser category). Comorbidities are not presented. Catheterization laboratory×regionalized is an interaction term equal to 1 if catheterization laboratory 
is present and community is regionalized. Reference categories include the following: not regionalized, year 2005, men, aged <40 years, White race, no 
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and Intervention Outcomes Network) Registry–Get 
With The Guidelines.29 This likely suggests that the pa-
tients, severity of illness, and hospitals we observed 
are similar to those seen in other population-based 
studies, whereas the ACTION Registry–Get With The 
Guidelines has a larger share of larger, tertiary care 
centers with greater resources.
Regionalization of STEMI care has been established 
in much of the United States and in other countries, 
but many areas still do not have such a system in place 
and, in those that do, its execution has been heteroge-
neous.30,31 Beyond the initial calls for regionalization by 
the American Heart Association and American College 
of Cardiologists, the Mission: Lifeline initiative has 
identified these systems as an important intervention 
to improve the outcomes of STEMI care; implementa-
tion and evaluation are ongoing.23,32,33 Understanding 
the collateral effects on a related condition, NSTEMI, 
is relevant to communities considering regionalization, 
particularly in communities with fewer resources.34,35 
Our results may improve policy makers’ expectations 
about the unintended consequences of establishing 
a regionalized system of STEMI care on patients with 
NSTEMI.
Our results also suggest that further research 
is needed to determine how patients are being se-
lected for angiography and possible PCI. Our finding 
that angiography (without PCI) and PCI were both 
associated with a 10 percentage point decrease in 
1-year mortality suggests that undergoing angiog-
raphy selects for healthier patients; our analysis of 
the predictors of angiography and PCI corroborates 
this, showing that younger patients with fewer co-
morbidities were more likely to undergo angiography. 
However, the administrative nature of our data set 
does not allow us to observe patient stability or other 
clinical factors informing the decision of whether to 
undergo angiography; patients may have been ap-
propriately deemed too sick to undergo an invasive 
strategy. Alternatively, an invasive strategy may not 
have been within the goals of care of some older 
patients with more comorbidities. Although our ret-
rospective design precludes causal inferences be-
tween early invasive therapy and mortality, it does 
Figure 2. Percentage of patients with non–ST-segment–elevation myocardial infarction (NSTEMI) undergoing angiography.
Percentage of patients in each year with NSTEMI who underwent angiography within 3 days of diagnosis (0–3d), who underwent 
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inform how angiography and PCI are used in practice 
and raises questions such as whether guidelines are 
being applied appropriately and whether and why 
subpopulations receive this intervention at different 
rates.
Limitations
Our study was limited to nonfederal hospitals in 
California, which is not necessarily representative of 
hospitals in other states or regions. It is, however, 
a large state with a diverse population and a wide 
range of urban and rural regions and could reflect 
trends seen in other regions and states within the 
United States. The increasing NSTEMI incidence and 
the increased likelihood of undergoing angiography 
reported in this study are consistent with trends re-
ported for other populations, as is the finding that the 
proportion of patients undergoing angiography is still 
suboptimal.27,36–38 Second, as with many administra-
tive data sets, the data sets we used did not provide 
detailed information about nonprocedural patient 
care (such as adherence to medical management 
guidelines), nor did it offer the opportunity to examine 
Table 3. Probability of Death Within 1 Year of NSTEMI
Variable Coefficient 95% CI P>t
Regionalized 0.000 −0.008 to 0.007 0.99
Year −0.009 −0.010 to −0.008 <0.0005
Patient characteristics
Women −0.019 −0.022 to −0.015 <0.0005
Age group, y
40–64 0.015 0.003 to 0.028 0.018
65–69 0.028 0.015 to 0.042 <0.0005
70–74 0.048 0.035 to 0.062 <0.0005
75–79 0.074 0.061 to 0.088 <0.0005
80–84 0.122 0.108 to 0.136 <0.0005
85–99 0.220 0.206 to 0.233 <0.0005
Race/ethnicity
Black −0.008 −0.015 to −0.002 0.008
Hispanic −0.015 −0.020 to −0.011 <0.0005
Asian −0.017 −0.022 to −0.011 <0.0005
Insurance
Medicare 0.014 0.009 to 0.019 <0.0005
Medicaid 0.007 0.001 to 0.014 0.03
Indigent −0.015 −0.026 to −0.003 0.011
Self-pay −0.005 −0.014 to 0.005 0.332
Other 0.000 −0.013 to 0.012 0.947
Hospital characteristics
ED volume (log) −0.001 −0.003 to 0.002 0.553
Critical access hospital 0.015 −0.036 to 0.066 0.564
Teaching hospital −0.010 −0.016 to −0.004 0.001
Government hospital 0.014 0.007 to 0.020 <0.0005
Not for profit −0.011 −0.015 to −0.006 <0.0005
County population (log) 0.150 0.055 to 0.245 0.002
Catheterization laboratory within hospital 0.037 0.030 to 0.043 <0.0005
Catheterization laboratory×regionalized 0.004 −0.003 to 0.012 0.246
Patient care
Angiography without intervention within 3 d −0.101 −0.105 to −0.097 <0.0005
PCI within 3 d −0.105 −0.110 to −0.101 <0.0005
Multivariable regression also includes other race/ethnicity categories (Native American, other, and invalid) and comorbidities (indicator variable for each 
Elixhauser category). Comorbidities are not presented. Catheterization laboratory×regionalized is an interaction term equal to 1 if catheterization laboratory 
is present and community is regionalized. Reference categories include the following: not regionalized, year 2005, men, aged <40 years, White race, no 
comorbidities, privately insured, and no catheterization laboratory in hospital. ED indicates emergency department; NSTEMI, non–ST-segment–elevation 
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social determinants of health, what treatments were 
offered but not rendered, or access to and quality 
of outpatient care. This also limited our ability to in-
vestigate whether other care recommendations were 
followed, such as immediate angiography and revas-
cularization for hemodynamically unstable patients 
or angiography within 24 hours for patients with high 
risk scores. Furthermore, coding could affect appar-
ent incidence if hospitals updated what they define 
as an NSTEMI during the regionalization process.39 
Also, our inclusion criteria relied on a primary diagno-
sis of NSTEMI acute myocardial infarction and could 
have mistakenly included patients with type 2 myo-
cardial infarction who were misclassified as having 
NSTEMI or excluded patients with NSTEMI who had 
this listed as a secondary diagnosis. However, unless 
there was a systematic difference in the way these 
were coded across regionalization areas, it is unlikely 
to pose significant problems in interpreting our final 
model.
Third, there are known changes in the epidemiolog-
ical features of acute myocardial infarction, in particu-
lar NSTEMIs, caused in part by increased sensitivity of 
troponin assays and changes in patient demographics 
and health-related risk factors, but it was beyond the 
scope of this study to investigate which assays were 
used or investigate state-wide changes in case mix.24,40 
Last, the decision by any given community to undergo 
regionalization of STEMI care may have been because 
of unobserved factors that also influenced care. For 
example, a community may have regionalized because 
it already functioned as if it were regionalized and thus 
the cost of regionalization was low, or because care 
was so poor or disorganized that the potential ben-
efits of regionalization were large. Similarly, we used 
a dichotomous variable for regionalization, although in 
practice regionalization exists on a spectrum, so the 
change from nonregionalized to regionalized may be 
large for one agency and small for another. Thus, we 
could not make any causal inferences between region-
alization and changes in treatment and outcomes for 
NSTEMI, but rather report the association between 
these 2 variables. Because there is considerable 
heterogeneity in how regionalization has been imple-
mented in other communities, our findings may not 
generalize to other regions.32
CONCLUSIONS
We found that STEMI regionalization policies were 
not associated with changes in angiography, PCI, or 
1-year mortality of patients presenting with NSTEMI. 
Mortality from NSTEMI is decreasing, and early 
invasive therapy is becoming increasingly com-
mon, but these trends are not attributable to STEMI 
regionalization policies and nearly half of patients with 
NSTEMIs still do not receive guideline-directed timely 
angiography. Policy makers should not expect STEMI 
regionalization programs to have either positive or 
negative unintended consequences for patients pre-
senting with NSTEMIs.
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Table S1. Probability of percutaneous coronary intervention (PCI) within 3 days of 
admission. 
 Coefficient [95% Conf. Interval] P>t 
Regionalized  -0.002 -0.008,0.004 0.508 
Year 0.005 0.004,0.006 <0.0005 
Patient characteristics   
Female -0.044 -0.047,-0.040 <0.0005 
Age group    
40-64 0.071 0.058, 0.084 <0.0005 
65-69 0.048 0.034, 0.062 <0.0005 
70-74 0.035 0.021, 0.049 <0.0005 
75-79 0.013 -0.002, 0.027 0.08 
80-84 -0.017 -0.031, -0.002 0.022 
85-99 -0.082 -0.096, -0.068 <0.0005 
Race / ethnicity    
Black -0.053 -0.060, -0.047 <0.0005 
Hispanic -0.025 -0.029, -0.020 <0.0005 
Asian -0.022 -0.028, -0.016 <0.0005 
Comorbidities no presented   
Insurance    
Medicare -0.026 -0.031, -0.021 <0.0005 
Medicaid -0.045 -0.051, -0.038 <0.0005 
Indigent 0.018 0.006, 0.031 0.003 
Self-pay -0.018 -0.028, -0.009 <0.0005 
Other -0.014 -0.027, -0.001 0.041 
Hospital characteristics    
ED volume (log) -0.007 -0.009, -0.004 <0.0005 
Critical access hospital -0.014 -0.069, 0.041 0.617 
Teaching hospital -0.002 -0.008, 0.004 0.506 
Government hospital -0.004 -0.011, 0.003 0.227 
Not for profit hospital 0.002 -0.003, 0.007 0.438 
County population (log) 0.371 0.276, 0.466 <0.0005 
Cath lab within hospital 0.311 0.307, 0.315 <0.0005 
 
ED – emergency department  
Multivariable regression also includes other race categories (Native American, other, invalid) and comorbidities (indicator variable 








Figure S1. Probability of death for NSTEMI patients associated with 
regionalization. 
 
Point estimate and 95% confidence intervals for the association between regionalization status and risk of death at various time 
points. Values were calculated from a series of multivariable regressions with death as the dependent variable, as presented in 
Table 3. 
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